Johnson & Johnson Leader Jennifer Taubert Named to Fortune's 2020 Most Powerful Women in Business List
Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19Did you enjoy reading this story? Click the heart.
Have Questions About Participating in a COVID-19 Vaccine Clinical Trial? A Doctor Overseeing a Study Helps Answer ThemDid you like reading this story? Click the heart to show your love.
Did you like taking this quiz? Click the heart to show your love.
The year 2020 has proven to be a challenging one, but it's also provided leaders the chance to really shine and support the companies—and the people—they serve in new and inspiring ways.
In tribute to her work as part of the Johnson & Johnson leadership team responsible for steering the company through an unprecedented year, Fortune has named Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, to its Most Powerful Women in Business list for 2020.
Leading With Purpose in Uncertain Times
Each year since 1998, Fortune has highlighted 50 women who are at the top of their industries on its annual list, using four criteria: the size and importance of the woman’s business in the global economy, the health and direction of the business, the arc of the woman’s career, and her social and cultural influence.
This year, a new criterion was added: how the executive is wielding her power. In this moment of uncertainty with the pandemic, how is she using her influence to help shape her company and the wider world for the better?
Johnson & Johnson commends Taubert on this repeat recognition, which reflects her relentless commitment to the patients who rely on the company’s transformational medicines.ShareDid you like reading this story? Click the heart to show your love.
Taubert, who has been honored for five years and moved up one spot on the list this year, heads the Janssen Pharmaceutical Companies of Johnson & Johnson. She leads the overall global strategy for the pharmaceuticals business, including overseeing the development of a Janssen investigational COVID-19 vaccine candidate and driving Janssen’s industry-leading portfolio, such as a new subcutaneous formulation of an existing medicine that reduces treatment time for patients living with multiple myeloma from several hours to three to five minutes.
She has also negotiated business deals to help improve the lives of patients with unmet medical needs, such as the recent acquisition of Momenta Pharmaceuticals, Inc.; fostered initiatives designed to ensure patient access and affordability; and served as a strong advocate for transparency in healthcare.
Johnson & Johnson commends Taubert on this repeat recognition, which reflects her relentless commitment to the patients who rely on the company’s transformational medicines.